- Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment
- Nolasiban safety profile not different from placebo in IMPLANT 2
- European MAA submission confirmed to be targeted for 4Q:19, commercial planning underway
- Nolasiban is a novel therapy and the first therapy of its kind to improve clinical pregnancy and live birth rates in women undergoing IVF
Wednesday, October 3, 2018
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.